TREM1 facilitates nonresponse to anti-TNF-α monoclonal antibodies in colitis via boosting ITCH/TAK1/caspase-8 axis-mediated macrophage pyroptosis.

Specifically, compared with the IgG1 control group, IFX treatment markedly attenuated body weight loss in the colitis model mice, while trends towards improvement were observed in the disease activity index, colon shortening, and histopathological damage in the IFX treatment group, although these differences did not reach statistical significance (Fig. 2 a-d).

also in 111,027 other papers